Selected data models

You must log in to select data models for download or further analysis.

5 Search results.
Relevance Rating New first Old first

Safety, tolerability, pharmacokinetics and pharmacodynamics of GSK1521498 in healthy subjects NCT00857883 - Pharmacogenetics; Inclusion; Temperature; Status of Treatment Blind; Study Conclusion

- 4/11/20 - 1 form, 6 itemgroups, 45 items, 1 language
Itemgroups: Administrative, PGx Consent, Inclusion, Temperature, Status of Treatment Blind, Study Conclusion
Study ID: 111314 Clinical Study ID: 111314 Study Title: A first-time-in-human, three-part, placebo-controlled, dose escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK1521498 in healthy subjects. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00857883 Sponsor: GlaxoSmithKline Phase: Phase 1 Study Recruitment Status: Completed Generic Name: GSK1521498 or placebo Study Indication: Obesity

The effect of intranasal capsaicin challenge model in healthy volunteers - 111611 - Period 1

- 3/13/19 - 1 form, 14 itemgroups, 93 items, 2 languages
Itemgroups: Administrative data, Vital Signs Pre-Challenge, Randomisation Number, Investigational Product (Dose), Vital Signs (Dosing), Temperature (Dosing), Hematology (Dosing), Clinical Chemistry, Electrocardiogram, Peak Nasal Inspiratory Flow Rate, Total Symptom Score, Visual Analogue Scale, Nostril Secretions, Pharmacokinetics - Blood
Study ID: 111611 Clinical Study ID: 111611 Study Title: A randomised, double-blind, placebo-controlled study to assess the effect of oral, single dose SB-705498 in a validated intranasal capsaicin challenge model in healthy volunteers. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00731250 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: SB-705498, Placebo, Caspaicin Trade Name: N/A Study Indication: Rhinitis

The effect of intranasal capsaicin challenge model in healthy volunteers - 111611 - Period 2

- 3/13/19 - 1 form, 12 itemgroups, 87 items, 2 languages
Itemgroups: Administrative data, Investigational Product (Dose), Vital Signs (Dosing), Temperature (Dosing), Hematology (Dosing), Clinical Chemistry, Electrocardiogram, Peak Nasal Inspiratory Flow Rate, Total Symptom Score, Visual Analogue Scale, Nostril Secretions, Pharmacokinetics - Blood
Study ID: 111611 Clinical Study ID: 111611 Study Title: A randomised, double-blind, placebo-controlled study to assess the effect of oral, single dose SB-705498 in a validated intranasal capsaicin challenge model in healthy volunteers. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00731250 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: SB-705498, Placebo, Caspaicin Trade Name: N/A Study Indication: Rhinitis

Immunogenicity and safety of Fluarix / Influsplit in young adults and elderly - 111631 - Diary Cards

- 3/11/19 - 1 form, 19 itemgroups, 85 items, 1 language
Itemgroups: Administrative data, LOCAL SYMPTOMS (at injection site), Local Symptoms - Redness, Local Symptoms - Swelling, Local Symptoms - Induration, Local Symptoms - Ecchymosis, Local Symptoms - Pain, OTHER LOCAL SYMPTOMS (from Day 0 to Day 20), MEDICATION, GENERAL SYMPTOMS, General Symptoms - Temperature, General Symptoms - Fatigue, General Symptoms - Headache, General Symptoms - Myalgia, General Symptoms - Shivering, General Symptoms - Arthralgia, General Symptoms - Sweating increase, OTHER GENERAL SYMPTOMS, Reminder
Study ID: 111631 Clinical Study ID: 111631 Study Title: A Phase III, open, non-randomized, multi-centric, single dose study to assess immunogenicity and safety of Fluarix / Influsplit SSW 2008/2009 injected intramuscularly in young adults (18 to 60 years) and in elderly (over 60 years). Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00706563 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: Influenza vaccine Trade Name: Fluarix Study Indication: Influenza

The Effect of Albiglutide on Cardiac Repolarisation Compared with Placebo 107085 - Screening Visit: Vital Signs Form

- 11/14/18 - 1 form, 2 itemgroups, 20 items, 1 language
Itemgroups: Administrative data, Vital Signs
Study ID: 107085 Clinical Study ID: GLP107085 Study Title: A Randomized, Double-blind, Parallel, Nested Crossover Study to Investigate the Effect of Albiglutide on Cardiac Repolarization (corrected QT Interval) Compared With Placebo in Healthy Male and Female Subjects: A Thorough ECG Study Employing Placebo, Albiglutide, and a Positive Control (Moxifloxacin) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01406262 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: albiglutide Trade Name: Tanzeum,Eperzan Study Indication: Diabetes Mellitus, Type 2

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial